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ABSTRACT
Different shades of World Trade Organization (WTO) agreement on 
trade-related intellectual property rights (TRIPS) are reflected in 
the Indian pharmaceutical industry, but small and medium-scale 
pharmaceutical firms are slowly increasing their product innovation, 
process innovation and research and development (R&D) intensity. 
Analysis of variance results highlight a significant difference in 
performance of sole proprietorship/partnership, private limited and 
public limited firms vis-à-vis product innovation, process innovation, 
increased range of goods and services, R&D intensity, new technology 
adoption and adaptation. Factor analysis results indicated that 
developing intellectual property rights (IPR), technological measures 
and marketing practices explained 80.256% of variation. Policy 
initiative factor is dominating and SMEs are still relying heavily on 
support from government.
1. Introduction
Is World Trade Organization (WTO) agreement on trade-related intellectual property rights 
(TRIPS) the key international agreement for promoting the harmonisation of national 
intellectual property right (IPR) regimes or does it merely guarantee minimum standards 
more than harmonisation? There are different viewpoints. The present study is a small 
attempt to gauge the impact of TRIPS on pharmaceutical small and medium enterprises 
(SMEs). The purpose of TRIPS, as stated in the preamble, is to introduce new rules and 
disciplines for global trade concerning the provision of adequate standards and principles 
concerning the availability, scope and use of TRIPS, for effective and appropriate means for 
the enforcement of TRIPS and for effective and expeditious procedures for the multilateral 
prevention and settlement of disputes between governments. The present study tries to 
analyse the IPR scenario and factors for promoting IPR culture in the post-TRIPS period 
through a survey of pharmaceutical firms.
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A brief reflection of the Indian pharmaceutical industry (IPI) is necessary to understand 
the changing scenario and relevance of TRIPS for IPRs. The IPI has been largely affected by 
various options and strategies available in Indian Patent Act 1970 focusing on the process 
patents. Thus, the domestic firms were able to introduce products patented by multinational 
corporations (MNCs) by making some minor changes in the manufacturing process. This 
act also restricted import of finished formulations and imposed high tariff rates.
The liberalisation of Indian economy has been the driving force for new technology and 
new products. Predominantly technology was imported, and only some scattered examples 
of firms investing in R&D to add their own value to the existing products were visible. 
Signing of TRIPS under WTO on 15 April 1994 changed the scenario. As part of this 
agreement, India has implemented product patent with effect from January 2005 imply-
ing a stringent IP environment. Thus, on account of liberalisation of the Indian economy 
and on account of new obligations undertaken by India under the TRIPS agreement, the 
adoption of new technology has become crucial for long-term growth of pharmaceutical 
industry. The Indian pharmaceutical sector grew by legally reverse-engineering interna-
tionally patented drugs. These changes at the global platform and at the national level have 
induced the pharmaceutical industry to adopt the rigour to enhance its competitiveness and 
productivity. Before adoption of TRIPs, patent act of 1970 was a key driver in the growth 
of the generics market in particular, and many companies were set up to reverse engineer 
new drugs patented in other counties and develop a new method of production. The drugs 
could be produced at lower prices.
India’s patent protection was weak and had adverse effects on international pharmaceuti-
cal and chemical firms. It is estimated that annual losses to the US pharmaceutical industry 
are $450 million, but Indian authorities have a different perspective. Processes for making 
drugs were patentable, but the patent term was limited to the five years from the grant of 
patent or seven years from the filing date of the patent application, whichever was shorter. 
Product patents in other areas were granted for 14 years from the date of filing. As per the 
obligations under WTO agreement, the Patents (Amendments) Act 1999 was passed in 
March 1999 to provide for exclusive marketing rights. The Patents (Second Amendment) 
Bill 1999 to further amend the patent Act 1970 and make it compliant with the TRIPS 
agreement to push towards product patenting and India introduced a comprehensive system 
of product patents in Jan, 2005.
Earlier focus of publish or perish is now on patent or perish (Bhanot & Kiran, 2013). 
Patents thus provide incentives for private sector investors to enhance their investments 
and thus help in their growth and development. The intangible nature of intellectual prop-
erty and the worldwide inconsistency of standard practices create challenges for those 
businesses wishing to protect their inventions, brands, and business methods in foreign 
markets. Patents are equally useful for small manufacturing enterprises (i.e. SMEs). Patents, 
it is generally felt benefits the owner of the IP and adds value to business concerns. Hence, 
all business corporations, whether SMEs or large, should have independent research and 
development (R&D) units. Providing free R&D facilities must be avoided. Proper docu-
mentation and maintenance of secrecy are considered as prime issues.
In this change, there is a need to understand the technology management strategies 
adopted by small and medium pharmaceutical firms in India to gear up for tougher patent-
ing regime. It is equally important to identify the factors for promoting IPR environment. 
Under Section 7 of the Micro, Small and Medium Enterprises Development (MSMED) Act, 
ECONOMIC RESEARCH-EKONOMSKA ISTRAŽIVANJA  875
2006, the Indian government defined a small enterprise is where the investment in plant and 
machinery is more than 25 lakh rupees but does not exceed 5 crore rupees; and a medium 
enterprise is where the investment in plant and machinery is more than five crore rupees 
but does not exceed ten crore rupees. There are many studies covering implications of TRIPs 
on large pharmaceuticals, but strategies adopted by small and medium firms need to be 
analysed to gain more insights on the impact of TRIPS on Pharmaceutical sector as a whole. 
The present study is a step in this direction covering up the following research questions.
i.   Is there a difference in patenting scenario of drugs and pharmaceutical industry in 
comparison to other sectors in post-TRIPs period?
ii.   Is there a shift towards adoption of technology management strategies after imple-
mentation of TRIPs by small and medium pharmaceutical firms?
iii.   What are the factors that promote IPR culture in small and medium pharma firms?
2. Review of literature and hypotheses development
It is pertinent to review implications of TRIPs on the IPI.
2.1. Implications of TRIPs on the IPI
There are diverse opinions regarding implications of strong patent regime on performance 
of the IPI. Dhar and Gopakumar (2006) reveal that the patent provisions in the TRIPS 
Agreement strengthened the existing trade monopolies and adversely pressurise technology 
diffusion between the north and the south. Kumar (2002) apprehends that strengthening of 
the IPR regime is likely to affect the prices of a large number of important drugs adversely 
and he opines that the strengthening of the IPR regime may limit the access of technology 
by developing country enterprises. Introduction of product patents is likely to increase drug 
prices and a strengthened IPR regime may actually slow down the pace of technological 
development by stifling the flow of R&D spill overs that are important inputs in research.
On the other hand, Lanjouw (1998) expressed that adherence to strong IPRs is good. 
Stronger IPRs may make the Indian environment more appealing to MNCs as a location 
for R&D. Mascus (2010) opines that strengthening the patent regime in developing coun-
tries with technologically imitative country such as India, would result in net expansion 
of OECD exports. Smith (2000), with more dissimulative industry-wise export data at 
state-level, has confirmed the substantial export expansion effect in the case of the US econ-
omy. Salazar, Falconi, Komen, and Cohen (2000) also strengthened the views expressed 
by Lanjouw (1998) and opine it would help research institutions to develop the means of 
protection and commercialisation of their technologies and products. The study by Grace 
(2004) reveals that one third of all FDA applications came from India in 2003 and would 
grow further.
Tancer (1999) feels that the intellectual property environment in a country affects the 
flow of foreign investment, particularly in those industries heavily dependent on intellec-
tual property protection. Following the TRIPS agreement, India is obligated to provide 
patent protection to the Pharmaceutical Industry by 2005. Gupta (2000) emphasises that 
in post-WTO patenting activity in U.S.A the private sector firms in the area of drugs and 
pharmaceuticals have shown the maximum interest to obtain patents. Smith (2000) has 
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argued that India has now reached a stage in pharmaceutical production where stronger 
IPRs would induce greater innovation by local firms. Athreye and Kapur (2009) also endorse 
this argument.
The study by Lalitha (2002) reveals that the much applauded IPI’s expertise in process 
development skills were achieved by positive amendments made to the Indian Patents 
Act 1970. This strength should be utilised to the get to the benefit from opportunities that 
arise from vertical disintegration of research, clinical trials and manufacturing by the mul-
tinationals. Kiran and Mishra (2009) report that the protection of IPR plays a dominant 
role in enhancing invention and innovation in the economy. The researchers analyse the 
patent scenario in India especially after the TRIPS agreement. The study also examines 
the patenting in India in the period of the 1990s and discusses that India still has to a long 
way to go and catch up with China and the US.In the light of these findings, the following 
hypothesis is proposed:
H1: Patent filing in drugs and pharmaceutical sector is higher as compared to other sectors in 
the post-TRIPS period
2.2. Firm size, type of organisation and firm performance
Ramanna (2002) highlights that from 1995 to 1998, India did not revise its patent laws as 
required by TRIPS. It was only the changing interest of industry groups by 1998–99, that 
were ultimately instrumental in forcing the government to implement full compliance to 
TRIPS and in evolving a pro-IPR constituency in India. Pradhan (2003) indicates that the 
observed R&D intensity of domestic firms is 2.6% and is three and half times than that 
of foreign firms, which is only 0.74%. Although with the implementation of TRIPS, the 
competitive pressure has worked efficiently in pushing Indian pharmaceutical firms into 
R&D activity, however its impact is likely to be limited to a few large and medium sized 
firms, as the large segment of small size firms lacks the huge resources that are required 
for product development.
Fink (2000) expresses that given India’s favourable cost structure, well-educated scien-
tists, English-speaking doctors who can supervise drug trials, India may well emerge as an 
attractive location for the conduct of R&D. Such a development would lead to additional 
long-term gains from strengthened patent protection. According to Dhar and Gopakumar 
(2006) the R&D spending of some of the leading firms has shown increase in Post- TRIPS 
period and hence R&D intensities of the firms have improved significantly. Sunil (2006) 
opines that the TRIPS compliance of the IPR regime has not reduced the innovation capacity 
of the domestic pharmaceutical industry which has visualised an increase in both research 
budget and patenting.
Chaturvedi and Chataway (2006) highlight that Indian firms are investing in R&D not 
only for new drug discovery but for developing capabilities to assimilate and exploit knowl-
edge available externally. They are also positioning themselves as a partner of choice for 
technology savvy national and multinational firms. As Srinivas (2004) reports, industrial 
Drugs and Chemical increased their share in global exports; therefore, the observed decline 
in value added and employment remains unexplained. SMEs employ more than 100 employ-
ers and generate employment. Gupta (2000) suggests that the IPI has stimulating opportu-
nities in the post-TRIPS period. Indian companies are accelerating their rate of DMF filings 
every quarter. IPRs have protected the innovation and products of the pharmaceuticals and 
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ANDA (abbreviated new drug application) filings with US FDA (United States Food and 
Drug Administration) are also increasing in the post-TRIPS period.
Aggarwal (2004) expressed that most of the R&D in Indian pharmaceutical firms is 
by large firms, supporting the suggestion that firm size bears a positive relationship with 
R&D. Chaudhuri (2007) further supported this view and opined that SME industries were 
primarily engaged with the development of new processes for manufacturing drugs, but 
now they are also involved in R&D for new chemical entities (NCE).
In the views of Chadha (2006), Indian firms are spending maximum resources to secure 
non-infringing process patents in foreign countries, especially of the growth of SME. 
According to Reddy (2006) the growth in R&D for SME and large scale pharmaceuticals is 
greater than the growth for the general pharmaceutical sector. Pharmaceuticals have huge 
resources to devote more investment for R&D and can afford to think about the future.
Further, Pandey and Shivesh (2007) highlight the fact that the performance of SME 
pharmaceutical firms in the Indian economy in terms of absolute growth in number of enter-
prises, employment, production and exports in the TRIPs period has improved. Pradhan and 
Sahu (2008) highlighted that the growth of SMEs plays an important role in structuring the 
Indian pharmaceutical market. Khalil Darwish and Singh (2013) highlight that the strong 
support for the involvement of human resource functions in business and corporate strat-
egy reduces employee turnover rate and enhances financial performance. Belwal, Belwal, 
and Al-Jabri (2014) opine that the training needs of employees should be kept in mind for 
better productivity. As highlighted by Tehseen and Ramayah (2015), external integration 
moderates the influence of entrepreneurial competencies on success of SMEs business which 
enhances the need for entrepreneurs to be competent enough to manage their relationships 
with their customers and suppliers to get competitive advantage.
Thus, this calls for a need to analyse the relation between firm size and organisation 
type on performance in the post-TRIPS Period. Size-wise the study focused on small and 
medium size and in organisation types, Sole proprietorship/ Partnership, Private limited 
and Public limited firms were analysed. The related hypotheses are:
H2: There is a relation between size of the firm and performance indicators: viz. sales, turnover, 
market share; profit; productivity; product cost; competitiveness; capital investment; and tech-
nological skills
H3: There is a relation between organisation form and performance indicators: viz. sales, turn-
over, market share; profit; productivity; product cost; competitiveness; capital investment; and 
technological skills
2.3. Adoption of technology management strategies
The next objective of the study was to understand the adoption of technology management 
strategies by selected pharmaceutical firms in the post-TRIPS period. Firms’ sustainable 
competitive advantage requires that the firms continuously differentiate their products 
and services from competitors (Chen, Hwa, Lee, Yu, & Wu, 2008; Koellinger, 2008). They 
proposed that if an idea has not been developed and transformed into a product, process, 
or service, or if it has not been commercialised, then it would not be classified as an inno-
vation. This provides an effective method of investigating the link between innovation and 
firm performance (Gopalakrishnan, 2000). Smith (2000) predicts that although the new 
patent regime has the potential to reward multinational corporations at the expense of 
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Indian firms, even then, the local firms are likely to benefit from stricter laws. The process 
of liberalisation (1991) has helped the domestic pharmaceuticals to develop policies that 
are focused on attracting domestic as well as international market and turn Indian market a 
global based industry, which has further transferred the Indian pharma industry in the pace 
of growth and increased competitiveness of Indian industry. They also examine that India is 
slowly moving into the global markets with international quality standards and prices and 
the future of the IPI hinges on patent protection. Technological collaboration is seen as a 
strategic mechanism to achieve certain objectives as highlighted (Bayona, Garcı́a-Marco, 
& Huerta, 2001; Hagedoorn, Link, & Vonortas, 2000): (1) to increase the technological 
capabilities of the firm; (2) to gain access to new markets and to exploit new business oppor-
tunities; (3) to have access to public funding; and (4) to complete the innovation process.
The process of liberalisation (since 1991) has helped domestic pharmaceutical firms to 
develop policies that are focused on attracting domestic as well as international market 
and turn Indian market a global based industry, which has further transferred the Indian 
pharma industry in the pace of growth and increased competitiveness of Indian industry. 
They also examine that India is slowly moving into the global markets with international 
quality standards and prices and the future of the IPI hinges on patent protection. Zacharias 
and Faraias (2002) have observed that the IPI is a successfully growing and high technology 
based industry. As opposite to this, Walker (2001) contends that TRIPS fails to help build 
‘innovative, ethical and sustainable societies’.
Kubo (2004) has examined the factors behind the observed patterns of R&D expenditure 
and patenting by Indian pharmaceutical companies after the signing of TRIPS agreement. 
He found that R&D intensity and the patent to R&D ratio have increased after 1995. The 
firms that produce both the bulk drugs and formulations are filing the majority of product 
patent applications as well as a large share of process patents than the firms specialising in 
bulk drugs only.
A study by Haakon (2004) suggests that as trade becomes more global the need for 
IPRs has increased in countries. Haakon mentioned the TRIPS perspective to encourage 
protection of new ideas in trade. It also highlights R&D on uniqueness, prompt creativity, 
innovation and invention. According to Chadha (2006), Indian firms are spending max-
imum resources to secure non-infringing process patents in foreign countries, especially 
for the growth of SMEs. Developing countries place more emphasis on drug master filings 
(DMFs) for bulk actives supply and ANDAs for formulations. Kavida and Sivakoumar 
(2008) express the view that innovation and IPRs can play a vital role in the acquiring new 
techniques of production in the economy with developments in information technology.
Brouwers, Silverstein, and Wolff (2004) similarly find that if countries imposing price 
controls were to remove them, R&D expenditures would increase by $17–22 billion, and 
between 10 and 13 new compounds a year would be introduced to the market. Srinivasan 
(1999) reports that industrial drugs and chemicals increased their share of global exports; 
therefore, the observed decline in added value and employment remains unexplained. 
According to Ullrich (2007), the settlement of patent infringement disputes is only to be 
considered under the ambit of cartel law in so far as the validity or the substantive scope of a 
property right is seriously in doubt. As highlighted by Mascus (2010) widespread violations 
of an innovator’s IPRs in developing countries have become a major international issue. 
Thus, these need to be tackled to encourage patents. SMEs employ more than 100 employers 
and generate employment. In light of this, it is pertinent to propose the next hypothesis:
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H4: There is a shift towards adoption of technology management strategies after implementation 
of TRIPs by small and medium pharmaceutical firms
2.4. Factors for promoting IPR Environment
The last step of research was to identify factors for promoting an IPR environment. The 
next research question is to understand which factors are important for promoting the IPR 
environment. The results of a research study (2007) by EXIM Bank’s Occasional Paper Series 
found that favourable government policies along with industry/firm level initiative have 
helped the industry to increase growth rates over the years. As highlighted in the study by 
Jain and Kiran (2012), the factors promoting IPRs could be either organisational factors or 
policy factors. Policy factors are prevalent more in developing countries, like in India we 
have TIFAC, patent facilitating centres which provide assistance at state or central level to 
promote IPR culture. Like in Punjab, we have a patent facilitating centre. We have Punjab 
state council of science and technology in Chandigarh to assist in patent search and literature 
review. Second type of measures could be those initiated by the organisations themselves.
The related hypothesis is:
H5: Policy initiative factors are more important than organisational factors
3. Design and methodology
3.1. Data collection
The sample was collected from north-east India. North-west region mainly comprises excise 
free zones and non-excise free zones ever since the central government announced the excise 
free zones in 2003 with the objective to help the development of backward and hilly areas of 
northwest India. The present research covers the excise free zones of Badi and Kala Amb in 
Himachal Pradesh and non-excise free zones of Mohali, Dehra Bassi, Lalru in Punjab. A ques-
tionnaire has been developed to study the post-TRIPS scenario in the pharmaceutical industry 
of India with reference to states Punjab, Haryana and Himachal Pradesh. The items along with 
author details are presented in Table 1. A random stratified sampling method has been adopted 
for the selection of the pharmaceutical companies. The firms with an annual sales turnover 
of between 100 and 300 crores as medium-scale firms and with an annual sales turnover of 
less than Rs. 100 crores have been classified as small-scale firms. Such firms are approximately 
1000 in number. Thus, the survey covers 1% of the firms. These SMEs have been chosen from 
northern India, a growing region of India. The reason for taking these enterprises is that most 
of them are export oriented units and must be innovators and it is good to understand their 
technology management strategies and know if they are investing in IPRs as well.
The pharmaceutical industry has gone through many phases. The IPI progressed with 
process innovation before 1991. This led to low prices for Indian drugs. The period 1995–
2008 (i.e. the post-TRIPS period) saw many changes in the IPI on IPR and Innovation front.
Around 300 firms were approached and 120 firms returned the questionnaire, out of 
which 100 complete in all respects have been taken up for analysis. The response rate is 
40%. The study covers the major areas in northwest India, where pharmaceutical firms are 
located viz. Mohali, Dehra Bassi, Lalru in Punjab; Baddi, Kala Aamb in Himachal Pradesh; 
and Ambala in Haryana. This has been depicted in Table 2.
880   R. KIRAN
3.2. Validity and reliability of the questionnaire
Table 3 depicts the section-wise reliability. The questionnaire is based on theory and empiri-
cal research. The item-wise details of the questionnaire along with an author index has been 
added through Table 3. The questionnaire was pretested for 20 firms. In case of technology 
management three questions were deleted on the basis of item-wise reliability. Thus, after 
deletion the reliability score for the constructs were greater than 0.70. The questionnaire 
had also been validated by the peers and has validation score of 3.75. Some questions were 
deleted and the changes suggested were incorporated in the questionnaire. The final ques-
tionnaire has been segmented into five sections. Section A covers the overall performance 
of the firms. Section B covers the status of IPR. Sections C and D deal with impact of TRIPS. 
Section C covers technology management strategies and has 21 items. Section D has four 
items related with exports. Section E covers measures for developing an IPR culture. It has 12 
Table 1. scale items with author details.
Scale items Authors
Technology management strategies
investment in R&D Blundell et al. (1999); hagedoorn et al. (2000); Bayona et al. 
(2001); jain and kiran (2012); koellinger, P. (2008).
increased range of goods and services Blundell et al. (1999); jain and kiran (2012)
nature of the firm Blundell et al. (1999); koellinger, P. (2008).
market share tehseen and Ramayah (2015); Blundell et al. (1999); 
koellinger, P. (2008).
Quality Gunasekaran et al. (1996)
Product flexibility Gunasekaran et al. (1996); Reddy (2006)
Reduced labour costs khalil Darwish and singh (2013); chen et al.
Reduced environment costs Brouwers et al. (2004).
status of iPRs kumar (2002); hagedoorn and cloodt (2003)
Factors for promoting IPR environment
internal training programme for R&D personnel on knowl-
edge related to iPRs
Belwal et al. (2014).
Reward the employee who has helped in acquiring iPRs
Get associated with indian Pharmaceutical alliance kumar (2002)
Expanding distribution network modell (2003);
Franchise manufacturing modell (2003)
Filing of iPRs (patents, trademarks, copyrights, trade 
secrets)
haakon (2004);
Pool patenting modell (2003); Bayona et al. (2001)
Reduction of taxes and fees Ullrich (2007)
Faster registration process modell (2003)
Government assistance for facilitating patent filing kiran and misra (2009)
support for entrepreneurial and managerial development Belwal et al. (2014)
severe penalty for iPR violation Ullrich (2007)
source: author created.
Table 2. sample pharmaceutical firms from northwest region.
Place of pharmaceutical firm State No. of units
Excise free zones Baddi himachal Pradesh 27
kala amb himachal Pradesh 25
total 52
non-excise free zones Lalru Punjab 8
mohali Punjab 8
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items with a reliability score measured by Cronbach Alpha of .801. The overall reliability of 
the questionnaire has been .842. Face and content validity has been used for questionnaire.
4. Firm-wise analysis
4.1. Status of IPRs
IPRs are playing a very important role in the pharmaceutical sector. The status of IPRs of 
drugs and pharmaceuticals with other sectors, as shown through Table 4, highlights that 
the chemical sector has shown a highest growth of 4.81% and 4.17% while electrical has 
lowest growth of 3.81%. The growth of food is 4.11%, of mechanical is 4.01% and general 
is 4.09%. This is indicative of the fact that drugs and pharmaceutical sector is a growing 
sector of the Indian economy. Thus the related hypothesis:
H1: Patent filing in drugs and pharmaceutical sector is higher as compared to other sectors in 
the post-TRIPS period
has been accepted.
In addition to this firm-wise analysis has also been done through primary data collected 
through questionnaire for various forms of IPR. The IPRS considered in the present study are: 
patents, copyrights, trademarks and trade secrets. As shown in Table 5, the results highlight 
that in terms of mean score the status of IPRS as reported by respondent firms is lower than 
that of medium firms, but one positive aspect is that in terms of trade marks the performance 
is better for both small and medium firms. Similarly for trade secrets the situation is better 
for medium scale firms. There is still much more effort needed by SMEs to improve their 
performance in terms of patents and copyrights. But one thing can be said that the situation is 
improving even for SMEs. Status of IPRs has improved and even SMEs are now indulging in the 
Table 3. item-wise reliability.
S No Items No. of items Cronbach alpha
1. overall performance of the firms 10 .802
2. status of intellectual property rights 08 .745
3. technology management strategies 21 .889
4. status of exports 4 .712
5. measures for developing iPR culture 12 .801
overall .842
source: authors’ calculations’.
Table 4. Patents granted scenario.
Year Chemical Drug Food Electrical Mechanical General 
1995–96 470 132 34 56 159 682
1996–97 282 71 18 54 142 340
1997–98 503 291 58 177 381 434
1998–99 609 150 35 138 462 406
1999–00 516 307 250 147 569 92
2000–01 353 276 72 142 254 221
2001–02 483 320 36 139 311 302
2002–03 399 312 67 118 228 255
2003–04 609 419 110 396 539 396
2004–05 573 263 67 245 414 349
2005–06 1140 508 140 451 1448 633
2006–07 1989 887 244 787 2526 1106
2007–08 4071 1783 554 1078 3230 5011
Growth rates 4.81** 4.17** 4.11** 3.81** 4.01** 4.09**
source: Growth rates authors’ calculations’.
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pace of innovation and inventions of new products and technology and trying to grab greater 
market share. With the new technology and product SMEs are now becoming an integral part 
of the supply chain for large pharmaceutical industries. Since there are many studies expressing 
concern over implementation of TRIPs, there is a need to study whether the performance of 
sample firms in terms of IPRs has improved in post- TRIPs scenario. A simple analysis on the 
basis of mean score reflects improvement in IPRS in Post-TRIPS scenario. This is reflection 
of simple numbers, while commercial aspects of IPRs are not covered in the current study.
4.2. Performance indicators
The results of the study shown in Table 6 highlight that small-scale pharmaceutical indus-
tries have performed well in terms of productivity, product cost, competitiveness, capital 
investment and technological skills. On the other hand medium scale pharmaceutical firms 
performed well in all other parameters. Thus results do reflect an improvement in perfor-
mance with size as medium scale performed well on all parameters. These results have 
been corroborated by Pandey and Shivesh (2007) and Pandey and Dixit (2009). This is an 
initial analysis which needs to be tested through t-test or analysis of variance (ANOVA). 
Thus, the next hypothesis:
H2: There is a relation between size of the firm and performance indicators: viz. sales, turnover, 
market share; profit; productivity; product cost; competitiveness; capital investment; and tech-
nological skills
has been accepted.
To gauge the organisation-wise results for performance ANOVA test was done. ANOVA 
helps to understand whether there has been a significant difference in the mean perfor-
mance indicators on the basis of the three organisational forms, viz. sole proprietorship/
partnership; private limited and public limited companies. The results of ANOVA have 
been depicted in Table 7.
ANOVA results shown through Table 7 highlight that ‘p-value’ is significant for sales, turnover, 
market share and profits. Thus, there is a significant difference in performance vis-à-vis sales, 
Table 5. status of intellectual property rights.
Type of firm Small Medium Total
Patents 2.36 2.50 2.64
copyrights 1.86 2.17 2.20
trademarks 3.07 3.17 3.20
trade secrets 2.57 3.00 2.80
source: authors’ calculations’.
Table 6. Firm-wise performance indicators.
Firm size/performance indicators Small Medium 
sales 2.00 3.33
turnover 2.07 3.00
market share 1.43 2.00
Profit 2.00 2.17
Productivity 3.93 3.83
Product cost 3.43 3.00
competitiveness 4.00 3.67
capital investment 3.17 3.00
technological skills 3.36 3.17
source: authors’ calculations’.
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turnover, market share and profits on the basis of form of organisation, viz. sole proprietorship/
partnership, private and public limited firm. In case of other parameters the mean scores are not 
significantly different. Thus on the basis of productivity, product quality, product cost, competi-
tiveness, capital investment and technological skills impact of organisational form is not visible 
in the sample firms. This supports the next hypothesis. Thus, 
H3: There is a relation between organisation form and performance indicators: viz. sales, turn-
over, market share; profit; productivity; product cost; competitiveness; capital investment; and 
technological skills
has been accepted.
Overall results show that SMEs have started adopting patents, copyrights, trademarks, 
and trade secrets and mark their significance in the pharmaceutical market. The situation 
is improving. Kubo (2004) has also established that R&D intensity and the patent to R&D 
ratio have increased after 1995. Gupta (2007) has also expressed that the IPI has stimulating 
opportunities in post-TRIPS period. The present study supports this increasing trend of 
patent filing in the post-TRIPS period in comparison to other sectors,. Earlier literature 
showed that MNCs and large firms were more active in filing IPRs, But current data is 
suggesting that patents are being filed by SMEs and this trend is indicative of better status.
Next step of research was to get an insight into technological status of sample firms by 
asking them to rate product, process or R&D intensity on a scale of 1–5, with 5 reflecting 
Table 7. anova: organisational form and performance indicators.
***sig. at 0.01% level; **sig. at 1% level; *sig. at 5% level. 
source: authors’ calculations’.
Organisational factors Sum of squares df Mean square F Sig.
sales Between groups 17.707 2 8.853 3.948 .034*
Within groups 49.333 22 2.242
total 67.040 24
turnover Between groups 20.431 2 10.216 5.093 .015**
Within groups 44.129 22 2.006
total 64.560 24
market share Between groups 28.411 2 14.206 8.626 .002***
Within groups 36.229 22 1.647
total 64.640 24
Profit Between groups 15.327 2 7.663 4.577 .022*
Within groups 36.833 22 1.674
total 52.160 24
Productivity Between groups 2.731 2 1.366 1.402 .267
Within groups 21.429 22 .974
total 24.160 24
Product quality Between groups 1.998 2 .999 .595 .560
Within groups 36.962 22 1.680
total 38.960 24
Product cost Between groups 1.131 2 .566 .505 .610
Within groups 24.629 22 1.119
total 25.760 24
competitiveness Between groups .827 2 .413 .323 .727
Within groups 28.133 22 1.279
total 28.960 24
capital investment Between groups .640 2 .320 .409 .669
Within groups 17.200 22 .782
total 17.840 24
technological skills Between groups .512 2 .256 .160 .853
Within groups 35.248 22 1.602
total 35.760 24
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high priority. The results reflected in Table 8 highlight that small- and medium-scale phar-
maceutical firms are slowly increasing their product innovation, process innovation, and 
R&D intensity. While for increased the of goods and services, medium scale firms have an 
edge over small scale, for new technology adaptation small firms have in fact a little higher 
mean score than medium scale firms. This reflects that size of the firm does lead to increase 
in the range of goods and services produced.
ANOVA was also applied and results (Table 9) are significant for product innovation, pro-
cess innovation, increased range of goods and services, R&D intensity and new technology 
adoption and technology adaptation. Thus there is a significant difference in performance of 
sole proprietorship/partnership and private and public limited firms vis-à-vis product inno-
vation (0.001), process innovation (0.006), increased range of goods and services (0.005), 
R&D intensity (0.050), new technology adoption (0.202) and new technology adaptation 
(0.012). Difference in technology parameters is visible on the basis of sole proprietorship/
partnership; private limited and public limited companies.
4.3. Technology management strategies and pharmaceutical firms
Factor analysis was undertaken on technology management strategies to classify them 
into smaller number of factors. Factor analysis clubs similar variables into same factor and 
facilitates further analysis. The related hypothesis is:
Table 9. anova: technology management strategy and pharmaceutical firms.
***sig. at 0.01% level; **sig. at 1% level; *sig. at 5% level. 
source: authors’ calculations’.
  Sum of squares df Mean square F Sig.
increase in product innovation Between groups 15.746 2 7.873 9.615 .001***
Within groups 18.014 22 .819
total 33.760 24
increase in process innovation Between groups 11.570 2 5.785 6.563 .006***
Within groups 19.390 22 .881
total 30.960 24
increased range of goods and 
services
Between groups 10.867 2 5.433 6.977 .005***
Within groups 17.133 22 .779
total 28.000 24
R&D intensity (the ratio of a 
company’s investment in R&D 
to its sales)
Between groups 7.850 2 3.925 3.322 .050*
Within groups 25.990 22 1.181
total 33.840 24
new technology adoption Between groups 5.992 2 2.996 1.723 .202
Within groups 38.248 22 1.739
total 44.240 24
new technology adaption Between groups 8.450 2 4.225 5.470 .012**
Within groups 16.990 22 .772
total 25.440 24
Table 8. status of technology management strategies.
Firm size/technology management strategies Small Medium Total
increase in product innovation 1.14 1.5 1.64
increase in process innovation 2.71 2.67 2.98
increased range of goods and services 2.5 3.17 3.06
R&D intensity 3.21 3.24 3.08
new technology adoption 2.86 2.67 2.52
new technology adaptation 2.71 2.33 2.32
source: authors’ calculations’.
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H4: There is a shift towards adoption of technology management strategies after implementation 
of TRIPs by small and medium pharmaceutical firms
Technology management strategies have been classified into three factors. The results 
are depicted through Table 10.
These strategies are:
i.   Developing IPR
ii.   Technological measures
iii.   Marketing practices
These three factors explain 80.256% of variation. The details of these along with sub-items 
are shown in Table 10. Developing IPR has emerged as most important factor with eigen-
value 2.094 and explaining 55.005% of variation.
Developing IPRs and technological measures are two important strategies reporting 
68.481 percent of total variation. Marketing practices strategies have reported lower vari-
ance as compared to other strategies. On the whole these three strategies explain 80.256% 
of variation. Thus, the next hypothesis:
H4: there is a shift towards adoption of technology management strategies after implementation 
of TRIPs by small and medium pharmaceutical firms
has been accepted.
4.4. Factors for developing IPR culture
Factor analysis was performed on variables influencing IPR culture. These included 12 
variables. The results are shown in Table 11. These were classified into two factors:
i.   Organisational factors
ii.   Policy factors
Table 10. technology adoption strategies.
Product attributes/factor Developing IPR Technological measures Marketing practices 
1. Product innovation .834
2. material and energy .780
3. Process invention .751
4. Enhanced collaborations (R&D) .699
5. managing practices .699
6. Production flexibility .613
7. R&D expenditure .513
Eigenvalue 2.094
% of variance 14.955
cumulative variance 55.005
8. new products .807
9. Labour costs .799
Eigenvalue 1.887
% of variance 13.476
cumulative variance 68.481
10. increased range of goods .868
11. Price strategy .832
Eigenvalue 1.649
% of variance 11.775
cumulative variance 80.256
source: authors’ calculations’.
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The related hypothesis is: 
H5: Policy initiative factors are considered more important than organisational factors in devel-
oping IPR culture
For understanding IPR environment factor analysis was performed on this construct. On 
the basis of factor analysis, two factors namely policy initiatives and organisational factors 
have been identified.
Organisational factors cover the following:
i.   Internal training programme for R&D personnel on knowledge related to IPRs
ii.  Reward the employee who has helped in acquiring IPRs
iii.   Get associated with Indian Pharmaceutical Alliance
iv.   Expanding distribution network
v.  Franchise manufacturing
vi.   Filing of IPRs (patents, trademarks, copyrights, trade secrets)
vii.   Pool patenting
In the organisational factors, filing of IPRs (patents, trademarks, copyrights, trade secrets) 
got highest loading and pool patenting the lowest loading. We are yet to develop a culture 
for pool patenting.
Policy initiative factors cover the following items:
i.   Reduction of taxes and fees
ii.   Faster registration process
iii.   Government assistance for facilitating patent filing
iv.   Support for entrepreneurial and managerial development
v.   Severe penalty for IPR violation.













3.54 36.79 36.79 internal training programme for R&D 












Expanding distribution network .695 4.34 .55 11
Franchise manufacturing .697 4.56 .70 10
Filing of iPRs (patents, trademarks, 
copyrights, trade secrets) 
.841 4.84 .72
3
Pool patenting .704 4.62 .68 8
mean of organisational initiatives 4.46
Policy 
initiatives
2.12 30.08 76.86 Reduction of taxes and fees .899 4.84 .48 2
Faster registration process .901 4.56 .54 1








severe penalty for iPR violation .655 4.31 .77 12
mean of policy factors 4.61
overall mean 4.53
source: authors’ calculations’.
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Policy initiative factors had higher mean score and higher loadings, signifying that the firms 
are yet not focusing on organisational policies to enhance their competitiveness and still 
relying upon government policies. Thus, the hypothesis that
H5: Policy initiative factors are considered more important than organisational factors in devel-
oping IPR culture
has been accepted.
5. Major findings of the study
The results depict that small- and medium-scale pharmaceutical firms are slowly increasing 
their product innovation, process innovation and R&D intensity. These results are corrob-
orated by Kiran and Mishra (2010) and Nair (2008). ANOVA results indicate a significant 
difference in product innovation, process innovation, increased range of goods and services, 
R&D intensity and new technology adoption and technology adaptation on the basis of 
forms of business organisation, viz. sole-proprietorship/partnership, private limited and 
public limited companies. This study indicates that even small-scale firms are into patent 
filing and they are competing with others in trademarks. Earlier literature supports this 
as is eminent from earlier studies (Chaudhuri, 2007; Grace, 2004). Blundell, Griffiths, and 
Van Reenen (1999) find a robust and positive effect of market share on observable head-
counts of innovations and patents although increased product market competition in the 
industry tends to stimulate innovative activity. Furthermore, the impact of innovation on 
market value is larger for firms with higher market shares. According to Hanel (2006), 
as a patent-friendly environment is now prevalent in India, patents are increasingly used 
for protecting innovations from imitation. But the results of the present study highlight 
the low filing of IPRs by manufacturing SMEs. These viewpoints are a contrast to those 
of Mosey, Clare, and Woodcock (2002) who suggest that the larger organisation manages 
knowledge and information more systematically.Developing IPRs, technological measures 
and marketing practices explained 80.256% of variation. Out of these, developing IPRs has 
emerged as the most important factor that explains maximum variation. Though techno-
logical measures need to be focused more to improve productivity as this will reduce cost 
of production and enhance competitiveness of firms. These thoughts are reverberated by 
Salazar et al. (2000) and Nair (2008).Policy initiative factors had higher mean score and 
higher loadings, signifying that the firms are yet not focusing on organisational policies to 
enhance their competitiveness and still relying upon Govt. Policies. In the organisational 
factors, filing of IPRs (patents, trademarks, copyrights, trade secrets) got highest loading 
and pool patenting the lowest loading. SMEs are yet to develop a culture for pool patenting.
The outcome of research has been presented through Figure 1. The study used respond-
ents from small scale and medium scale to find out factors essential for developing IPR 
Conducive environment. These stakeholders helped in understanding technology manage-
ment strategies followed by SMEs. These three strategies identified are: (i) developing IPRs; 
(ii) technological measures and (iii) marketing practices.
Regarding factors for promoting IPR culture, two factors are: (i) policy measures and 
(ii) organisational measures.
The results reflect that SMEs are still relying more on policy measures and regarding 
organisational measures, some initiatives have been started, like organising IPR training pro-
grammes, but these measures are still in nascent stage. Stage is not yet set for interdisciplinary 
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and inter-organisational sharing is still low. Pool patenting could be a solution, but it has 
not emerged as important factor for sample SMEs.
6. Recommendation for further research
Future research should be focused on in-depth study of patenting activity, R&D and exports 
by taking case studies of some selected pharmaceutical companies. Case studies of successful 
firms can be of great help for the policy makers as well as for the pharmaceutical firms.
In this competitive environment the Pharmaceutical Industry of India is passing through 
various phases. Firms like Dr. Reddy’s lab are into innovative drug manufacturing and are 
actively filing up IPRs. The generics market is passing through difficult phase and even big 
companies like Ranbaxy had suffered the consequences of this. There is an emergence of 
Tax free zones in North-western region of India. Baddi (Himachal Pradesh) and Kala Amb 
(Haryana) are being flooded by new pharmaceutical firms. Baddi in Himachal Pradesh is 
being quoted as the new pharma capital. All pharma firms are into Drug manufacturing 
filings and ANDA filings have also improved in the post-TRIPS period. Thus the pharma-
ceutical industry of India is facing a lot of challenges in view of these changes. A time has 
come for them to indulge in filing more IPRs for enhancing global competitiveness.
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